Valley Brook Capital Group Inc. Sells 50 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Valley Brook Capital Group Inc. lowered its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 6.7% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 700 shares of the company’s stock after selling 50 shares during the period. Valley Brook Capital Group Inc.’s holdings in IDEXX Laboratories were worth $389,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. OFI Invest Asset Management acquired a new position in IDEXX Laboratories during the 3rd quarter worth about $25,000. Valley National Advisers Inc. lifted its holdings in IDEXX Laboratories by 84.6% during the 4th quarter. Valley National Advisers Inc. now owns 48 shares of the company’s stock worth $26,000 after buying an additional 22 shares during the period. Geo Capital Gestora de Recursos Ltd acquired a new position in IDEXX Laboratories during the 3rd quarter worth about $28,000. Covestor Ltd lifted its stake in shares of IDEXX Laboratories by 71.8% in the 3rd quarter. Covestor Ltd now owns 67 shares of the company’s stock valued at $29,000 after purchasing an additional 28 shares during the period. Finally, Whittier Trust Co. of Nevada Inc. lifted its stake in shares of IDEXX Laboratories by 108.6% in the 3rd quarter. Whittier Trust Co. of Nevada Inc. now owns 73 shares of the company’s stock valued at $32,000 after purchasing an additional 38 shares during the period. Institutional investors own 87.84% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on IDXX shares. Barclays dropped their price objective on IDEXX Laboratories from $655.00 to $570.00 and set an “overweight” rating on the stock in a research note on Thursday. Piper Sandler downgraded IDEXX Laboratories from an “overweight” rating to a “neutral” rating and set a $525.00 price objective on the stock. in a research note on Tuesday, January 30th. JPMorgan Chase & Co. boosted their price objective on IDEXX Laboratories from $600.00 to $630.00 and gave the company an “overweight” rating in a research note on Tuesday, February 6th. The Goldman Sachs Group boosted their price objective on IDEXX Laboratories from $500.00 to $650.00 and gave the company a “buy” rating in a research note on Wednesday, January 17th. Finally, William Blair reaffirmed an “outperform” rating on shares of IDEXX Laboratories in a research note on Tuesday, April 9th. Four research analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $580.88.

IDEXX Laboratories Stock Up 1.0 %

IDXX stock traded up $4.78 during trading on Friday, reaching $480.60. 547,954 shares of the stock were exchanged, compared to its average volume of 509,434. The company has a current ratio of 1.57, a quick ratio of 1.17 and a debt-to-equity ratio of 0.40. The firm’s 50 day moving average is $523.29 and its 200 day moving average is $513.58. The firm has a market cap of $39.69 billion, a P/E ratio of 46.52, a price-to-earnings-growth ratio of 3.78 and a beta of 1.27. IDEXX Laboratories, Inc. has a twelve month low of $372.50 and a twelve month high of $583.39.

IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings data on Monday, February 5th. The company reported $2.32 EPS for the quarter, topping analysts’ consensus estimates of $2.12 by $0.20. The firm had revenue of $901.60 million during the quarter, compared to analyst estimates of $891.88 million. IDEXX Laboratories had a return on equity of 63.66% and a net margin of 23.26%. The company’s revenue for the quarter was up 8.8% on a year-over-year basis. During the same period in the previous year, the company posted $2.05 EPS. As a group, research analysts forecast that IDEXX Laboratories, Inc. will post 11.05 EPS for the current year.

Insiders Place Their Bets

In other IDEXX Laboratories news, SVP George Fennell sold 8,198 shares of the business’s stock in a transaction that occurred on Thursday, February 8th. The stock was sold at an average price of $573.87, for a total transaction of $4,704,586.26. Following the completion of the sale, the senior vice president now directly owns 6,712 shares of the company’s stock, valued at approximately $3,851,815.44. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, CEO Jonathan Jay Mazelsky sold 12,000 shares of the company’s stock in a transaction that occurred on Wednesday, February 7th. The stock was sold at an average price of $572.61, for a total value of $6,871,320.00. Following the completion of the transaction, the chief executive officer now directly owns 79,247 shares of the company’s stock, valued at $45,377,624.67. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, SVP George Fennell sold 8,198 shares of the company’s stock in a transaction that occurred on Thursday, February 8th. The shares were sold at an average price of $573.87, for a total value of $4,704,586.26. Following the completion of the transaction, the senior vice president now directly owns 6,712 shares of the company’s stock, valued at $3,851,815.44. The disclosure for this sale can be found here. In the last ninety days, insiders sold 43,524 shares of company stock valued at $24,871,960. Corporate insiders own 2.11% of the company’s stock.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.